Tesamorelin VS MK677

Although Tesamorelin and MK677 share similarities in their effects on the growth hormones, they work in different ways. Tesamorelin is an analog of the naturally occurring growth hormone-releasing hormone, whereas MK677 is a ghrelin receptor agonist. Despite working separately, they influence similar areas in preclinical models. 

So, how is it possible, and what is the science behind it? Here is a detailed answer in this blog. We have discussed the detailed nature, structure, similarities, and key differences of Tesamorelin vs MK677. 

What is Tesamorelin?

Buy Tesamorelin

Tesamorelin is a synthetic analog of the naturally occurring growth hormone-releasing hormone. It consists of 44 amino acid molecules that are connected by peptide bonds. Initially, it was developed to study its impacts on lipodystrophy (excess visceral fat) in preclinical models. 

Over time, scientists have investigated the compounds for various conditions in controlled laboratory settings. Some early studies suggest its connection with growth hormone secretion from the pituitary gland in preclinical models. Elevated growth hormone levels may influence parameters involved in muscle preservation, adipose tissue metabolism, and the rapid recovery of skeletal health in preclinical models.  

What is MK677?

Buy MK-677

MK677 is a synthetic growth hormone secretagogue, meaning it has the potential to stimulate growth hormone secretion in preclinical models. Scientists are investigating the compound in various studies related to growth hormone deficiency. Some preclinical studies also suggest that it elevates growth hormone levels in experimental models. 

This potential was observed due to the close connection between MK677 and the pituitary gland. Its binding to ghrelin receptors triggers pituitary signaling pathways associated with growth hormone secretion in preclinical models. In this way, an elevated growth hormone level may be observed during MK677 laboratory experiments.

Mechanism of Action

• Tesamorelin: After administration in preclinical models, Tesamorelin may bind to growth hormone-releasing hormone receptors. This binding may influence the pituitary gland’s growth hormone-secreting patterns in preclinical models. Elevated growth hormone levels may also affect pathways involved in IGF-1 secretion in preclinical models. 

• MK677: After being administered to preclinical models, MK677 may bind with ghrelin receptors and activate them. This activation influences the pituitary gland to trigger more growth hormone into the bloodstream in preclinical models. Elevated growth hormone levels may also alter IGF-1 secretion patterns in experimental models. Together, growth hormones and IGF-1 influence multiple pathways in preclinical models. 

Side-By-Side Comparison of Tesamorelin and MK677

Although Tesamorelin and MK677 are two different compounds, they share some similarities. Here is a detailed analysis of the key similarities and differences between them: 

Key Similarities Between Tesamorelin and MK677
Similarities	Tesamorelin	MK677
Impact on the Hypothalamus	Tesamorelin acts on the hypothalamus in the pituitary gland by binding to growth hormone-releasing hormone receptors.	MK677 also influences the hypothalamus-pituitary axis by binding ghrelin receptors in preclinical models.
Growth Hormone Secretion	Tesamorelin alters the patterns of growth hormone secretion, elevating basal growth hormone levels in preclinical models.	MK677 also alters the parameters involved in growth hormone secretion. This may also elevate the basal growth hormone levels in preclinical models.
IGF-1 Secretion	Elevated growth hormone levels in the bloodstream influence pathways involved in IGF-1 secretion in preclinical models.	Similarly, improved growth hormone levels may alter pathways involved in IGF-1 secretion in preclinical models.
Muscle Hypertrophy	Growth hormones have the potential to preserve muscle and alter patterns of rapid muscle recovery, leading to muscle hypertrophy in preclinical models.	Similarly, the improved growth hormone levels may also preserve muscle mass and aid rapid recovery of muscle tissue. This may also result in muscle hypertrophy in preclinical models.
Skeletal Health	Growth hormones may also alter osteoblast activity, potentially affecting skeletal health in preclinical models.	Similarly, improved growth hormone levels may also affect osteoblast activity, which is involved in skeletal health in preclinical models.
Legal Status	Tesamorelin is only permitted for laboratory research. Its human consumption is strictly prohibited.	Similarly, MK677 is also only permitted for laboratory experiments. Its human consumption is also strictly prohibited.

 

Key Differences Between Tesamorelin and MK677
Differences	Tesamorelin	MK677
Nature and Structure	Tesamorelin is a synthetic growth hormone-releasing hormone analog with the potential to act on the hypothalamus-pituitary axis in preclinical models.	MK677 is a growth hormone secretagogue that has the potential to modulate growth hormone secretion in preclinical models.
Mechanism of Action	Tesamorelin acts by binding to growth hormone-releasing hormone receptors in preclinical models.	MK677 acts by binding to ghrelin receptors in the pituitary gland in preclinical models.
Administration	Tesamorelin is administered subcutaneously as an injection in preclinical models during laboratory experiments.	MK677 is administered orally in capsule form to preclinical models during laboratory studies.
Half Life	Tesamorelin has a short half-life. It may remain in preclinical models for up to 2 hours.	Whereas MK677 has an extended half-life up to 24 hours in preclinical models.
Effects on Appetite	Tesamorelin has neutral impacts on the parameters associated with appetite regulation in preclinical models.	MK677 has a substantial impact on the patterns associated with appetite regulation in preclinical models.

Associated Side Effects of Tesamorelin and MK677

The associated side effects of Tesamorelin and MK677 are as follows: 

Side Effects of Tesamorelin	Side Effects of MK677
Injection site reaction	Increased appetite
Itching	Water retention
Swelling	Fatigue
fatigue	Joint pain
headache	Mild numbness
Mild nausea	Headache
dizziness	Dizziness

Note: These side effects were observed during early experiments on the compounds. Therefore, they may vary from subject to subject. 

Legal Status

As far as the legal status of the compounds is concerned, they are still under preclinical trials. Therefore, they are not allowed for human consumption. However, researchers and scientists may use them for laboratory experiments in controlled environments. 

Final Thought

Tesamorelin and MK677 are two different synthetic compounds. Despite their different structures, they share effects on muscle hypertrophy, skeletal health, and growth hormone levels in preclinical models. Besides their potential impacts, they may also cause some side effects, including mild nausea, numbness, fatigue, and headache in experimental models. 

Frequently Asked Questions (FAQs)

Where can I buy Tesamorelin and MK677 online?

You can buy Tesamorelin and MK677 online from BehemothLabz. 

What is Tesamorelin used for in laboratory studies?

Tesamorelin is used to assess its effects on the growth hormone secretion in preclinical models. 

How long does it take for Tesamorelin to work in the system? 

In preclinical studies, Tesamorelin has shown activity within the first few hours after administration. 

What are the results of MK677 after 2 months of experimentation? 

After 2 months of administration, researchers observed a significant rise in the basal growth hormone levels in preclinical models. 

How long does it take for MK677 to work in the system? 

According to preclinical studies, MK677 may take a few hours to affect various parameters in the system. However, its visible results may take a month or more. 

References: 

1. Wang, Ying, and Brian Tomlinson. “Tesamorelin, a human growth hormone-releasing factor analogue.” Expert Opinion on Investigational Drugs 18.3 (2009): 303-310.
2. Stanley, Takara L., et al. “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.” The Lancet HIV 6.12 (2019): e821-e830.
3. Grunfeld, Carl, Argyris Dritselis, and Peter Kirkpatrick. “Tesamorelin.” Nature Reviews Drug Discovery 10.2 (2011): 95-97.
4. Falutz, Julian, et al. “Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.” Aids 22.14 (2008): 1719-1728.
5. Loss, Fat. “What is Ibutamoren? A Comprehensive MK 677 Review.”
6. Yoon, SeJeong, et al. “Ibutamoren mesylate: Summary Report.” (2021).